‌

US Patent 11958893 Methods for modulating an immune response

Patent 11958893 was granted and assigned to Cue Biopharma on April, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent

Current Assignee

Cue Biopharma

Date Filed

July 21, 2021

Date of Patent

April 16, 2024

Patent Applicant

Cue Biopharma

Patent Application Number

17381858

Patent Citations

‌

US Patent 7670595 Fc-interferon-beta fusion proteins

‌

US Patent 7098306 Method and compositions for treating hepatocellular cancer

‌

US Patent 7186804 IL-2 fusion proteins with modulated selectivity

‌

US Patent 7432351 B7-H1 variants

‌

US Patent 9284349 Peptide vaccines for cancers expressing tumor-associated antigens

‌

US Patent 9359424 Multimeric polypeptides of HLA-G including alpha1-alpha3 monomers and pharmaceutical uses thereof

‌

US Patent 9494588 Gene coded for a MHC class I molecule, plasmid, expression system protein, multimer, reagent and kit to analyze a T cell frequency

‌

US Patent 10059750 Modified toxins

‌

US Patent 10272042 Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatment

‌

US Patent 10501521 Disulfide-linked multivalent MHC class I comprising multi-function proteins

•••

Patent Inventor Names

Ronald D. Seidel, III

Rodolfo J. Chaparro

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

11958893

Patent Primary Examiner

CPC Code

Find more entities like US Patent 11958893 Methods for modulating an immune response

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API

By using this site, you agree to our Terms of Service.